Molecular markers for prostate cancer: An update

Aims and objectives of this presentation
There are at least three different sets of molecular markers for the diagnosis and aggressiveness of prostate cancer on the market. Are the currently available data sufficient for clinical use in the setting of active surveillance or clinical decision making for or against adjuvant treatment? This session will present the latest data on molecular markers for prostate cancer. In addition high quality data on conventional prognostic markers will be discussed.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (+) are 3 minutes in length, followed by 3 minutes for discussion.

09:08 - 09:18

Molecular markers in prostate cancer: What is currently available?
S. Loeb, New York (US)

Validation of the novel 5-group Gleason grading system: 3+5 disease risk may be overestimated
By: Van den Bergh R.C.N.¹, Van Der Kwast T.², De Jong J.³, Zargar H.⁴, Murphy D.G.⁵, Van Der Poel H.G.⁵

Institutes: Royal Melbourne Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²Toronto, Dept. of Pathology, Toronto, Canada, ³NKI, Dept. of Pathology, Amsterdam, The Netherlands, ⁴Royal Melbourne Hospital, Dept. of Urology, Melbourne, Australia, ⁵Amsterdam, Dept. of Urology, Amsterdam, The Netherlands

*726

Temporal trends in prostate cancer (PCa) risk group stratification following the 2008 United States preventive services task force recommendations
By: Abdollah F.F.H.¹, Dalela D.¹, Sood A.¹, Sammon J.¹, Karabon P.¹, Meyer C.², Sun M.², Choueiri T.³, Menon M.¹, Trinh Q.D.²

Institutes: ¹Henry Ford Hospital / Health System, Dept. of Urology, Detroit, United States of America, ²Brigham and Women’s Hospital / Dana-Farber Cancer Institute, Harvard Medical School, Dept. of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America, ³Brigham and Women’s Hospital / Dana-Farber Cancer Institute, Harvard Medical School, Dept. of Medical Oncology, Boston, United States of America

*727

Inverse stage migration: Contemporary results of 140.253 North American prostate cancer patients treated with radical prostatectomy from 2004 to 2012
By: Leyh-Bannurah S-R.¹, Dell’Oglio P.², Fisch M.², Graefen M.¹, Karakiewicz P.², Briganti A.², Montorsi F.², Budäus L.¹

Institutes: ¹Martini-Clinic, Prostate Cancer Center, Hamburg, Germany, ²Urological Research Institute, IRCCS San Raffaele Scientific Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ³University Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁴University of Montreal Health Center, Dept. of Cancer Prognostics and Health Outcomes, Montreal, Canada

*728

Transcriptome-wide expression study reveals biomarker signature with prognostic potential for prostate cancer
**Poster Session 58**

**729**

**Utilization of a genomic classifier for prediction of metastasis following postoperative salvage radiation therapy**

*By: *Karnes J.R.¹, Cheeurng V.², Howard L.³, De Hoedt A.³, Du Plessis M.², Yousefi K.², Lam L.², Buerki C.², Traublisi E.J.², Dicker A.P.², Davicioni E.², Freedland S.J.³, Den R.B.²*

*Institutes:* Mayo Clinic, Dept. of Urology, Rochester, United States of America, ²GenomeDx Biosciences, Dept. of Clinical Operations, Vancouver, Canada, ³Duke University, Dept. of Urology, Durham, United States of America, ⁴Thomas Jefferson University, Sidney Kimmel Medical College, Philadelphia, United States of America

---

**730**

**Decipher genomic classifier measured on prostate biopsy predicts 10 year metastasis risk**

*By: *Klein E.¹, Neumann S.², Yousefi K.², Haddad Z.², Lam L.², Wang Q.², Cheeurng V.², Palmer-Aronsten B.², Buerki C.², Davicioni E.², Li J.², Kattan M.W.³, Stephenson A.J.², Magi-Galluzzi C.⁴

*Institutes:* Cleveland Clinic, Glickman Urological and Kidney Institute, Cleveland, United States of America, ²GenomeDx Biosciences, Dept. of Clinical Operations, Vancouver, Canada, ³Cleveland Clinic, Dept. of Quantitative Health Sciences, Cleveland, United States of America, ⁴Cleveland Clinic, Dept. of Anatomic Pathology, Cleveland, United States of America, ⁵Genomedx Biosciences, Dept. of Marketing, Vancouver, Canada

---

**731**

**The power of a genomic classifier to assess cancer persistence and biochemical failure in patients post-prostatectomy**

*By: *Woodlief T., Rocco B., Ganapathi H., Ogaya G., Mouraviev V., Patel V.

*Institutes:* Florida Hospital, Global Robotics Institute, Celebration, United States of America

---

**732**

**CCP-score improves the current risk assessment in newly diagnosed prostate cancer patients**

*By: *Oderda M.¹, Cozzi G.², Barale M.¹, Garelli G.¹, Gurioli A.¹, Daniele L.³, Sapino A.³, Renne G.¹, De Cobelli O.², Gontero P.¹

*Institutes:* University of Turin, Dept. of Surgical Sciences/Urology, Turin, Italy, ²Istituto Europeo Di Oncologia, Dept. of Urology, Milan, Italy, ³A.O.U. Città Della Salute E Della Scienza, Dept. of Pathology, Turin, Italy, ⁴Istituto Europeo Di Oncologia, Dept. of Pathology, Milan, Italy

---

**733**

**Heterogeneity in circulating tumor cells (CTCs) in blood samples of metastatic castration-resistant prostate cancer (mCRPC) patient: Comparison of isolation techniques**

*By: *Theil G., Weiß C., Fischer K., Schumann A., Fornara P.

*Institutes:* UKH Universitätsklinikum Halle (Saale), Dept. of Urology and Kidney Transplantation, Halle/Saale, Germany

---

**734**

**Highly-trained dogs’ olfactory system for detecting biochemical recurrence following radical prostatectomy**

*By: *Taverna G.², Tidu L.³, Grizzi E.¹, Stork B.⁴, Seveso M.², Bozzini G.², Sardella P.², Latorre G.³, Lughezzani G.³, Buffi N.⁵, Guazzoni G.⁵, Mandreschi A.²

*Institutes:* Humanitas Research Hospital, Dept. of Immunology and Inflammation, Rozzano, Italy, ¹Humanitas Mater Domini, Dept. of Urology, Castellanza, Italy, ²Italian Ministry of Defense, Dept. of Veterinary Center, Grosseto, Italy, ³West Shore Urology, Dept. of Urology, Michigan, United States of America, ⁴Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy

---

**735**

**What is the prognostic impact of nodal tumour burden in patients with a single positive node at final pathology?**
By: Nini A.¹, Lucianò R.², Freschi M.², Fossati N.¹, Gandaglia G.¹, Castiglione F.³, La Croce G.¹, Saitta G.¹, Bertini R.¹, Doglioni C.², Montorsi F.¹, Briganti A.¹

Institutes: ¹IRCCS Ospedale San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy, ³University Hospitals Leuven, Dept. of Urology, Leuven, Belgium

Prognostic value of lymphovascular invasion in robot-assisted radical prostatectomy patients with prostate confined, resection margin negative tumour
By: Kang Y.J.¹, Jang W.S.¹, Kwon J.K.¹, Yoon C.Y.¹, Lee J.Y.¹, Cho K.S.¹, Ham W.S.¹, Cho I.R.², Choi Y.D.¹

Institutes: ¹Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ²Inje University, College of Medicine, Dept. of Urology, Goyang, South Korea